Form D · Biotechnology
Renasant Bio, Inc.
Berkeley, CA · CIK 0002075979
Offering snapshot reported Jul 14, 2025 · SEC filing
- Reported sold
- $25.5M Offering amount: $25.5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2025 | Initial | $25,461,184 | No comparison | 3 | SEC filing |
| Jul 14, 2025 | Initial | $30,000,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-551566
Source: Form D, filed Jul 14, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin Bitterman | Director |
| Evan Caplan | Director |
| Emily Conley | Director, Executive |
| Anna French | Director |
| Thomas Gustafson | Executive |
| Natalie Holles | Director |
| June Lee | Director |
| Charlotte Mc Kee | Director |
| Deborah Palestrant | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2630 Bancroft Way #507
Berkeley, CA, 94704
Berkeley, CA, 94704